Assessment of SLEDAI score changes in systemic lupus erythematosus patients under low-dose interleukin-2 therapy: A meta-analysis

IF 2.3 Q2 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH

Clinical Epidemiology and Global Health Pub Date : 2024-07-26 DOI:10.1016/j.cegh.2024.101704

Dwi Soelistyoningsih , Hani Susianti , Handono Kalim , Kusworini Handono , Jonny Karunia Fajar

{"title":"Assessment of SLEDAI score changes in systemic lupus erythematosus patients under low-dose interleukin-2 therapy: A meta-analysis","authors":"Dwi Soelistyoningsih , Hani Susianti , Handono Kalim , Kusworini Handono , Jonny Karunia Fajar","doi":"10.1016/j.cegh.2024.101704","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Interleukin-2 is being investigated as a potential therapeutic option in systemic lupus erythematosus (SLE), but the current findings regarding its effectiveness remained inconclusive.</p></div><div><h3>Objectives</h3><p>To assess the association between the administration of low-dose interleukin-2 and the SLE Disease Activity Index (SLEDAI) score among SLE patients.</p></div><div><h3>Methods</h3><p>A meta-analysis was conducted by gathering articles from Scopus, Pubmed, and Embase databases (PROSPERO registration ID: 451971). Essential data from each study was extracted, and the impact of administering low-dose interleukin-2 on the SLEDAI score in SLE patients was assessed using the inverse variance method.</p></div><div><h3>Results</h3><p>We conducted an analysis of 7 articles involving 194 patients. Our study revealed that the administration of low-dose interleukin-2 was associated with a decrease in the SLEDAI score, showing an average reduction of −4.3 points from baseline. Furthermore, when comparing SLE patients treated with standard of care plus low-dose interleukin-2 to those receiving standard of care alone, we observed a significantly greater improvement in the SLEDAI score, with an average difference of 2.91 points.</p></div><div><h3>Conclusion</h3><p>Our results indicate the potential beneficial impact of low-dose interleukin-2 in reducing disease activity and enhancing outcomes in SLE management.</p></div>","PeriodicalId":46404,"journal":{"name":"Clinical Epidemiology and Global Health","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213398424002008/pdfft?md5=931666fd634ed1d9c5d6a6e06a528bde&pid=1-s2.0-S2213398424002008-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Epidemiology and Global Health","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213398424002008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Interleukin-2 is being investigated as a potential therapeutic option in systemic lupus erythematosus (SLE), but the current findings regarding its effectiveness remained inconclusive.

Objectives

To assess the association between the administration of low-dose interleukin-2 and the SLE Disease Activity Index (SLEDAI) score among SLE patients.

Methods

A meta-analysis was conducted by gathering articles from Scopus, Pubmed, and Embase databases (PROSPERO registration ID: 451971). Essential data from each study was extracted, and the impact of administering low-dose interleukin-2 on the SLEDAI score in SLE patients was assessed using the inverse variance method.

Results

We conducted an analysis of 7 articles involving 194 patients. Our study revealed that the administration of low-dose interleukin-2 was associated with a decrease in the SLEDAI score, showing an average reduction of −4.3 points from baseline. Furthermore, when comparing SLE patients treated with standard of care plus low-dose interleukin-2 to those receiving standard of care alone, we observed a significantly greater improvement in the SLEDAI score, with an average difference of 2.91 points.

Conclusion

Our results indicate the potential beneficial impact of low-dose interleukin-2 in reducing disease activity and enhancing outcomes in SLE management.

查看原文本刊更多论文

评估接受低剂量白细胞介素-2疗法的系统性红斑狼疮患者的SLEDAI评分变化：一项荟萃分析

背景白细胞介素-2作为系统性红斑狼疮（SLE）的一种潜在治疗选择正在接受研究，但目前有关其有效性的研究结果仍不确定。方法通过收集Scopus、Pubmed和Embase数据库（PROSPERO注册编号：451971）中的文章进行了一项荟萃分析。我们提取了每项研究的基本数据，并使用逆方差法评估了施用低剂量白细胞介素-2对系统性红斑狼疮患者SLEDAI评分的影响。我们的研究显示，施用低剂量白细胞介素-2与SLEDAI评分的下降有关，与基线相比平均下降了-4.3分。结论我们的研究结果表明，低剂量白细胞介素-2在减少疾病活动和提高系统性红斑狼疮治疗效果方面具有潜在的益处。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Epidemiology and Global Health PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-

CiteScore

4.60

自引率

7.70%

发文量

218

审稿时长

66 days

期刊介绍： Clinical Epidemiology and Global Health (CEGH) is a multidisciplinary journal and it is published four times (March, June, September, December) a year. The mandate of CEGH is to promote articles on clinical epidemiology with focus on developing countries in the context of global health. We also accept articles from other countries. It publishes original research work across all disciplines of medicine and allied sciences, related to clinical epidemiology and global health. The journal publishes Original articles, Review articles, Evidence Summaries, Letters to the Editor. All articles published in CEGH are peer-reviewed and published online for immediate access and citation.